Preclinical studies demonstrate that CDK4/6i treatment markedly enhances the efficacy of PD-1/PD-L1 checkpoint inhibitors, primarily by augmenting the immunogenicity of tumor cells [128]. Here, PDCD1 is linked to neoplasm.